)
Bausch Health (BHC) investor relations material
Bausch Health Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
14th consecutive quarter of revenue and Adjusted EBITDA growth excluding Bausch + Lomb; quarterly Adjusted EBITDA exceeded $1B for the first time.
Q3 revenue was $2.941B, up 10% reported and 8% organically; Adjusted EBITDA attributable to Bausch Health Companies Inc. rose 32% to $1.305B.
Strong first-nine-month results supported a second consecutive quarterly increase to FY 2026 guidance for revenue, Adjusted EBITDA and adjusted cash flow from operations excluding Bausch + Lomb.
Financial highlights
Q3 operating income was $983M versus $619M; GAAP net income attributable to shareholders was $436M, or $1.15 per diluted share, versus $179M, or $0.48.
Adjusted gross margin was 75%, up 230 bps; adjusted cash flow from operations was $782M, up $274M or 54%.
Consolidated cash provided by operating activities was $813M, up 101%; adjusted net income attributable to shareholders was $673M versus $434M.
Nine-month revenue rose 11% to $8.317B; a $1.426B Salix goodwill impairment contributed to a $729M net loss.
Excluding Bausch + Lomb, Q3 revenue was $1.566B, up 12%; adjusted cash flow from operations was $539M, up $192M.
Outlook and guidance
FY 2026 consolidated revenue guidance increased to $10.975B–$11.175B and Adjusted EBITDA guidance to $4.315B–$4.415B.
FY 2026 guidance excluding Bausch + Lomb: revenue $5.525B–$5.625B, Adjusted EBITDA $3.225B–$3.275B and adjusted cash flow from operations $1.600B–$1.675B.
Guidance excluding Bausch + Lomb implies midpoint growth of 8% for revenue, 13% for Adjusted EBITDA and 29% for adjusted cash flow from operations.
Bausch + Lomb FY 2026 guidance is revenue of $5.450B–$5.550B and Adjusted EBITDA of $1.090B–$1.140B.
Q4 XIFAXAN gross-to-net accruals for the 2027 Medicare price change are expected to reduce revenue growth by 800 bps and Adjusted EBITDA growth by 1,400 bps; inventory normalization may reduce growth by a further 300 and 500 bps, respectively.
- Q2 2026 saw double-digit growth, record margins, raised guidance, and a $1.43B Salix impairment.BHC
Q2 2026 - Sustained growth, robust liquidity, and strategic flexibility underpin future value creation.BHC
Barclays 30th Annual Leveraged Finance Conference 2026 - Sustained growth, China expansion, and BLCO monetization drive strategic priorities.BHC
RBC Capital Markets Global Healthcare Conference 2026 - All director nominees, executive pay, and auditor appointment were approved by majority vote.BHC
AGM 2026 - Double-digit revenue and EBITDA growth, but a $1.43B goodwill impairment drove a net loss.BHC
Q1 2026 - Board recommends approval of all proposals, with strong focus on pay-for-performance and ESG.BHC
Proxy filing - 11th straight quarter of revenue and EBITDA growth, with strong outlook and lower net debt.BHC
Q4 2025 - Q3 revenue up 12%, Adjusted EBITDA up 10%, guidance raised, and net loss narrowed.BHC
Q3 2024 - Q2 2024 revenue up 11% to $2.40B, adjusted EBITDA up 10%, and guidance raised.BHC
Q2 2024
)
)
)
)
)
)
)
)